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Objective: Pelvic endometriosis was found to be associated with oxidative stress in the peritoneal cavity.
Endogenous melatonin was known for its antioxidative activities, and oral melatonin had been studied as
a treatment option for endometriosis. However, the association between endogenous melatonin and
endometriosis has not yet been determined.
Materials and methods: A cross-sectional case-control study was implemented. Blood and urine samples
from women with surgically conﬁrmed ovarian endometriomas, benign adnexal tumors other than
endometriomas, and healthy volunteers were collected and tested for cancer antigen 125 (CA125) as well
as urinary 6-sulfatoxymelatonin (aMT6s), a surrogate for average serum melatonin level.
Results: A total of 97 patients with endometriomas, 59 with benign ovarian tumors other than endo-
metriomas, and 80 women without adnexal lesion were recruited. Elevated serum CA125 and decreased
body mass index were found in patients with ovarian endometriosis (both p < 0.01). Urinary creatinine-
adjusted aMT6s was not associated with the presence of endometriosis (p ¼ 0.88). A statistically
nonsigniﬁcant negative correlation between urinary creatinine-adjusted aMT6s and CA125 (p ¼ 0.16) in
patients with ovarian endometriosis was found.
Conclusion: Endogenous melatonin might not be a major determinant for the occurrence of endome-
triosis. A potential negative correlation between endogenous melatonin and the severity of endome-
triosis merits further investigations.
Copyright © 2015, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Endometriosis is deﬁned as the presence of endometrial tissue
outside the uterine cavity, which may cause chronic inﬂammatory
reactions.1 It is an estrogen-dependent disease and affects
approximately 10e15% of women of reproductive age.2 The growth
of endometriotic tissue is thought to be stimulated by estrogen and
cytokines.3 Studies also suggested that oxidative stress is a poten-
tial factor inﬂuencing the inﬂammatory reaction associated withs of interest relevant to this
s and Gynecology, National
eng-Li Road, Tainan 70428,
. Wu).
for Gynecologic Endoscopy and Minimendometriosis.4,5 Macrophages are the predominant immune cells
in the peritoneal cavity. The amount of macrophage is increased in
the peritoneal ﬂuid of patients with endometriosis, and the ma-
jority of the macrophages are in a hyperactive status.6 It was re-
ported that elevated reactive oxygen species are produced by
macrophages in the peritoneal ﬂuid in patients with pelvic endo-
metriosis.7 Murphy et al8 also found an increase in concentration of
oxidized low-density lipoproteins in the peritoneal ﬂuid of women
with endometriosis. Although some studies, aimed to measure the
reactive oxygen species directly in the peritoneal ﬂuid fromwomen
with endometriosis, failed to show a signiﬁcant higher antioxidant
status, local oxidative stress was still suspected to be present at the
endometriotic lesions.4
Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine
produced by the pineal gland. Its synthesis increases nocturnally.
Serum melatonin has a short half-life and is rapidly metabolized.ally Invasive Therapy. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Levels of creatinine-adjusted urinary aMT6s and serum CA125.
Urinary aMT6s/creatinine
Mean (range)
Serum CA125, U/mL
Mean (range)
Normal control 49.9 (39.1e60.6) N/A
Endometrioma group 51.6 (41.7e61.5) 84.5 (71.2e97.7)
Benign tumor group 47.3 (32.1e62.6) 27.8 (20.6e35.1)
p ¼ 0.88a p < 0.001b
aMT6s ¼ 6-sulfatoxymelatonin; CA125 ¼ cancer antigen 125; N/A ¼ not available.
a One-way analysis of variance.
b t test.
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sulfatoxymelatonin (aMT6s), is excreted in urine. The measure-
ments of urinary aMT6s have been demonstrated to correlate well
with its concentration in plasma.9 Studies have suggested that
melatonin may play a role in the pathogenesis of human repro-
ductive processes.10 Melatonin could protect oocytes from free
radical damage and improve oocyte quality and fertilization rates.11
It functions in a variety of ways to reduce oxidative stress. It is also a
powerful direct free radical scavenger.12,13 The antioxidative activ-
ities of melatonin and its metabolites may have potential roles in
the pathophysiology of endometriosis. In a rat model, pinealectomy
showed a signiﬁcant effect on the progression of endometriosis
explants, and the effect could be reversed by intraperitoneal
administration of melatonin.14 Increased apoptotic cells in the
endometriotic zone were found under the treatment of melatonin,
suggesting that melatonin may be a therapeutic option for endo-
metriosis.15 A randomized controlled trial further demonstrated
the efﬁcacy of melatonin in the treatment of endometriosis with a
signiﬁcant decrease in dysmenorrhea and daily pain scores.16
However, whether the analgesic effect is attributed to the regres-
sion of endometriotic lesions or simply to the antinociceptive effect
of melatonin has yet to be clariﬁed.
Cancer antigen 125 (CA125) is a cell surface antigen mainly
known as a biomarker of ovarian cancer. It has been reported that
serum CA125 was elevated in patients with endometriosis, and the
level of CA125was correlatedwith the severityof endometriosis.17,18
The diagnostic sensitivity was poor according to a meta-analysis
study. Using receiver operating characteristic curves, at a speci-
ﬁcity of 90%, a sensitivity of 28% was reported for endometriosis of
all severities. In patients with advanced diseases, a better diagnostic
performance was found, with a sensitivity of 47% at a speciﬁcity
of approximately 90%.18 Nevertheless, serum CA125 is helpful
following treatment of endometriosis in evaluating recurrent dis-
ease if elevated CA125 was found during the follow-up courses.19
To our knowledge, there is no prior study investigating the as-
sociation between the endogenous melatonin level and the pres-
ence of endometriosis. We hypothesize that patients with
endometriosis have a lower level of serum melatonin compared
with the melatonin level in the general population. The aim of this
study was to determine the level of urinary aMT6s in women with
endometriosis and to examine the relationship between aMT6s and
CA125, wherein CA125 was taken as an index for the severity of
endometriosis.
Materials and methods
Women aged 20 years to 45 years whowere ﬁrst diagnosedwith
endometriomas and other benign ovarian tumors between January
1, 2009 and December 31, 2011 at the National Cheng Kung Uni-
versity Hospital (Tainan, Taiwan) were enrolled in the study. All of
the study participants received laparoscopic surgeries of either
oophorectomy or oophorocystectomy for ovarian tumors. The study
was approved by the institutional review board of the National
Cheng Kung University Hospital, and all participants provided
informed consent. Each study participant was examined for uni-
lateral or bilateral adnexal tumors by ultrasonography. Blood
samples were collected and tested for the level of serum CA125
prior to surgical treatment.
First-void morning urine was collected from each patient for the
measurement of urinary aMT6s in the preoperative period. The
concentration of aMT6s in urine was determined using an enzyme-
linked immunosorbent assay kit (IBL Immunobiological Labora-
tories, Hamburg, Germany). The urinary aMT6s level was stan-
dardized (divided) by the urinary creatinine level of the same
sample and used as a substitute for average melatonin levels.9The diagnosis of endometriosis was made surgically and
conﬁrmed by surgical pathology. Participants with adnexal tumors
other than endometriomas, such as mature cystic teratoma and
serous cystadenoma, served as positive controls. Moreover, urine
samples from a cohort of female volunteers who had no ovarian
tumor on ultrasound examinations were collected as negative
controls in a decoded manner.
Statistical analyses were performed using the STATA 12 (Stata-
Corp, College Station, TX, USA) statistical software package. Student
t test, analysis of variance, and linear regression analysis were
applied where appropriate.Results
A total of 97 patients with endometriomas, 59 with benign
ovarian tumors other than endometriomas, and 80 womenwithout
adnexal lesions were recruited in this study. The average ages for
the study group (the endometrioma group), positive control group
(other benign tumors group), and negative control group were 33.8
years, 32.7 years, and 33.1 years, respectively, which were not
statistically different according to a one-way analysis of variance
(p ¼ 0.629). The body mass index (BMI) values for the study group,
positive control group, and negative control group were 21.0, 22.6,
and 22.5, respectively. A signiﬁcantly lower BMI was found in
participants with endometriomas compared with those without
endometriomas (p ¼ 0.008).
A marginally nonsigniﬁcant negative correlation was found
between age and urinary creatinine-adjusted aMT6s in participants
without endometrioma according to the linear regression analysis
(p ¼ 0.067). By contrast, BMI was not associated with the level of
urinary creatinine-adjusted aMT6s (p ¼ 0.169).
Participants with unilateral or bilateral endometriomas had
signiﬁcantly higher pretreatment serum CA125 compared with
those who presented with other benign ovarian tumors (p < 0.001).
The mean CA125 level of the endometrioma group was 84.5 U/mL
(95% conﬁdence interval, 71.2e97.7 U/mL). The average concen-
tration of serum CA125 for those with benign ovarian tumors was
27.8 U/mL (95% conﬁdence interval, 20.6e35.1 U/mL). The mean
concentrations of serum CA125 in participants with unilateral
endometrioma and those with bilateral endometriomas were not
signiﬁcantly different (78.6 U/mL and 93.0 U/mL, respectively;
p¼ 0.29). The levels of urinary aMT6s and serum CA125 of the three
study groups are presented in Table 1. No statistically signiﬁcant
difference was found in the standardized urinary aMT6s across the
three study groups (p ¼ 0.88).
We further investigated the association between levels of serum
CA125 and urinary aMT6s. Table 2 shows the urinary creatinine-
adjusted aMT6s level according to different levels of CA125 in
patients with endometriomas. A trend of lower urinary aMT6s
concentrations in patients with a higher serum CA125 was found,
but it was not statistically signiﬁcant according to the linear
regression analysis (p ¼ 0.161).
Table 2
Urinary creatinine-adjusted aMT6s level corresponding to levels of CA125 in pa-
tients with endometriomas.
CA125, U/mL Urinary aMT6s/creatinine pa
<39.99 48.2 (33.6e62.9) 0.21
39.99e69.06 63.6 (35.7e91.5)
69.06e111.66 58.7 (34.5e83.0)
>111.66 36.7 (23.6e49.9)
aMT6s ¼ 6-sulfatoxymelatonin; CA125 ¼ cancer antigen 125.
a One-way analysis of variance.
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Our study results demonstrated a signiﬁcantly lower BMI in
patients with endometriomas compared with those with benign
ovarian tumors aside from endometriosis. The ﬁnding was
compatible with our previous report.20 Moreover, several studies
also revealed an inverse association between BMI and the severity
of endometriosis.21e24 It is still debatable whether the low BMI is a
cause or a consequence of endometriosis. Shah et al24 found that
women with surgically conﬁrmed endometriosis have a relatively
low BMI since age 18 years, proposing that the impact of BMI on
endometriosis precedes the diagnosis, but not the onset, of endo-
metriosis. In the present study, which has a cross-sectional study
design, a causal relationship between BMI and endometriosis
cannot be made.
CA125 is known as a surrogate for the severity of endometriosis.
In patients with minimal endometriosis classiﬁed using the staging
system of the American Fertility Society, serum CA125 levels were
not found to be elevated in a variety of studies and therefore may
not be a useful tool for either diagnosis or disease follow up.25
However, in women with mild to severe pelvic endometriosis,
elevated serum CA125 levels were correlated with the revised
American Fertility Society stage of endometriosis, especially in
patients with deeply inﬁltrated endometriosis and/or endome-
triomas.25 A signiﬁcantly higher serum CA125 was found in our
study participants with endometriomas compared with those who
have other benign ovarian tumors, which is compatible with the
ﬁndings in the literature.
In a recent study testing for an oxidative stress marker, 8-
hydroxy-2-deoxyguanosine, in the peritoneal ﬂuid of women
with endometriosis, a signiﬁcantly higher level of the marker was
found in patients with endometriosis compared with controls.5 8-
Hydroxy-2-deoxyguanosine, which can be measured in urine, is a
known biomarker of oxidative stress and widely used ﬁngerprint of
DNA damage by free radicals.26 Davanipour et al27 found that in
older women with a lower level of physiological melatonin pro-
duction, there was a signiﬁcantly higher urinary 8-hydroxy-2-
deoxyguanosine. Interestingly, women of reproductive age did
not show this correlation. These ﬁndings implicated that younger
women generally have a better ability to clean the reactive oxida-
tive species, at least in part, through a higher level of melatonin
compared with older women because melatonin level generally
declines with age. In our study, the urinary creatinine-adjusted
aMT6s was not signiﬁcantly different between patients with and
without endometriosis, indicating that endogenous melatonin
might not be a major determinant of the occurrence of endome-
triosis. Nevertheless, a negative correlation between CA125 and
urinary creatinine-adjusted aMT6s, although not reaching a sta-
tistical signiﬁcance, was found in patients with higher CA125
within the endometrioma group. Because the serum level of CA125
has been correlated with the extent of endometriotic lesions in the
pelvis,28 the potential inverse correlation between CA125 and uri-
nary aMT6s suggested that endogenous melatonin level might be
associated with the severity of pelvic endometriosis. We deem thisﬁnding important for several reasons. First, it is possible that the
signiﬁcance could be found by simply expending the sample size.
Second, because increased oxidative stress has been used to
quantify the severity of endometriosis,29 it is plausible that
endogenous melatonin could be lower in patients withmore severe
endometriosis.
What is truly interesting, but yet to be clariﬁed, is whether a
more severe endometriotic lesion is contributed by a lower
endogenous melatonin, or the melatonin level is reduced owing to
the increased consumption by free radicals from severe endome-
triosis. These two hypotheses are not mutually exclusive, and could
both be true. It has been reported that physical or environmental
stressors that cause an elevated oxidative status would upregulate
melatonin synthesis, whereas intensive oxidative stress could
rapidly consume melatonin and lead to a reduced endogenous
melatonin.30 Similar questions were raised in other cases, such as in
acute stroke. A lower urinary aMT6s level was found in patients
with acute stroke compared with normal controls, but whether the
low aMT6s is the consequence or the potential cause of acute stroke
is still unknown.31,32 Further investigations are necessary to vali-
date these hypotheses.
In summary, this study is the ﬁrst report on endogenous mela-
tonin levels in women with endometriosis. An elevated serum
CA125 and a decreased BMI in patients with ovarian endometriosis
were found. Urinary creatinine-adjusted aMT6s, a surrogate for
average serum melatonin level, was not signiﬁcantly different be-
tween patients with ovarian endometriomas and those without
endometriosis. A nonstatistically signiﬁcant negative correlation
between urinary creatinine-adjusted aMT6s and serum CA125 in
patients with ovarian endometriosis was found. The ﬁnding was
intriguing and merits future studies to investigate the association
between endogenous melatonin and the condition of endometri-
osis. The results of this studywill serve as a reference to understand
the underlyingmechanism for treating endometriotic patients with
exogenous melatonin.Acknowledgments
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